Commissioning of an ultra-high dose rate pulsed electron beam medical LINAC for FLASH RT preclinical animal experiments and future clinical human protocols

Treatment Use

FLASH-RT

Cancer Indication

Electron-beam FLASH

Number of Patients

0

Summary/Conclusion

The Mobetron device was evaluated with electron beams of 9 MeV in conventional (CONV) mode and of 6 and 9 MeV in UHDR mode (nominal energy). The acceptance was performed according to the acceptance protocol of the company. The commissioning consisted of determining the short- and long-term stability of the device, the measurement of percent depth dose curves (PDDs) and profiles at two different positions (with two different dose per pulse regimen) and for different collimator sizes, and the evaluation of the variability of these parameters when changing the pulse width and pulse repetition frequency. Measurements were performed using a redundant and validated dosimetric strategy with alanine and radiochromic films, as well as Advanced Markus ionization chamber for some measurements.

Read More

Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes

Treatment Use

Mobetron

Cancer Indication

Pancreatic

Number of Patients

158

Summary/Conclusion

A retrospective review of 158 patients who received IORT in the setting of biopsy-proven BR/LA PDAC following NAT between 2008 and 2017 was performed. The Kaplan–Meier method was used to analyze progression-free survival (PFS) and overall survival (OS) of FOLFIRINOX treated patients.

Read More

Treatment of a first patient with FLASH-radiotherapy

Treatment Use

FLASH-RT

Cancer Indication

Electron-beam FLASH

Number of Patients

1

Summary/Conclusion

When compared to conventional radiotherapy (RT) in pre-clinical studies, FLASH-RT was shown to reproducibly spare normal tissues, while preserving the anti-tumor activity. This marked increase of the differential effect between normal tissues and tumors prompted its clinical translation. In this context, we present here the treatment of a first patient with FLASH-RT.

Read More

Long-term neurocognitive benefits of FLASH radiotherapy driven by reduced reactive oxygen species

Treatment Use

FLASH-RT

Cancer Indication

Electron-beam FLASH

Number of Patients

0

Summary/Conclusion

We highlight the potential translational benefits of delivering FLASH radiotherapy using ultra-high dose rates (>100 Gy·s−1). Compared with conventional dose-rate (CONV; 0.07–0.1 Gy·s−1) modalities, we showed that FLASH did not cause radiation-induced deficits in learning and memory in mice. Moreover, 6 months after exposure, CONV caused permanent alterations in neurocognitive end points, whereas FLASH did not induce behaviors characteristic of anxiety and depression and did not impair extinction memory.

Mechanistic investigations showed that increasing the oxygen tension in the brain through carbogen breathing reversed the neuroprotective effects of FLASH, while radiochemical studies confirmed that FLASH produced lower levels of the toxic reactive oxygen species hydrogen peroxide. In addition, FLASH did not induce neuroinflammation, a process described as oxidative stress-dependent, and was also associated with a marked preservation of neuronal morphology and dendritic spine density. The remarkable normal tissue sparing afforded by FLASH may someday provide heretofore unrealized opportunities for dose escalation to the tumor bed, capabilities that promise to hasten the translation of this groundbreaking irradiation modality into clinical practice.

Read More

IORT with Electrons in Breast Cancer: 10-Year Results

Treatment Use

Electron IORT

Cancer Indication

Breast (Boost)

Number of Patients

770

Summary/Conclusion

This study provides 10-year outcome data of 770 stage I through III breast cancer patients who received intraoperative electron radiation therapy (IOERT) as a tumor bed boost preceding whole breast irradiation. After a median follow-up period of 121 months, 21 in-breast recurrences (2.7%) occurred with triple-negative and HER2fl subtypes as negative predictors. As confirmed in long-term follow-up, IOERT has been demonstrated to be a viable boost strategy in any risk constellation.

Read More